title: Rituximab and lupus interstitial lung disease: friend or foe?
authors.forename: Petros
authors.initials: P
authors.lastname: Efthimiou
authors.forename: Manil
authors.initials: M
authors.lastname: Kukar
authors.forename: Alissa
authors.initials: A
authors.lastname: Hersh
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012129:Respiratory Function Tests; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D006886:Hydroxychloroquine; D011239:Prednisolone; D009173:Mycophenolic Acid